Amylase
A digestive enzyme produced primarily by the pancreas and salivary glands. Elevated blood amylase levels are a diagnostic indicator of pancreatitis. Amylase monitoring is relevant to GLP-1 receptor agonist safety surveillance, given the pancreatitis signal associated with this drug class.
Technical Context
Serum amylase: produced by pancreas (P-isoamylase, ~40% of total) and salivary glands (S-isoamylase, ~60%). Elevated amylase: acute pancreatitis (typically >3× ULN, peaks at 12-72 hours, returns to normal in 3-5 days), salivary disease (mumps, parotitis), bowel obstruction, renal failure (reduced clearance), macroamylasaemia (amylase-immunoglobulin complex — falsely elevated, benign). Amylase is less specific for pancreatitis than lipase — amylase can be elevated from multiple non-pancreatic sources. For GLP-1 RA safety monitoring: routine amylase/lipase screening is not required, but these tests should be obtained promptly if a patient develops persistent severe abdominal pain (potential pancreatitis). In GLP-1 RA clinical trials, mild amylase/lipase elevations (without clinical pancreatitis) are observed more frequently in treated vs placebo groups — clinical significance is debated.